Time to change the focus with a new treatment for primary aldosteronism

Edouard Mills(Imperial College Healthcare NHS Trust), Fausto Palazzo(Hammersmith Hospital), Florian Wernig(Imperial College Healthcare NHS Trust), Karim Meeran(Imperial College London), Amir H. Sam(Charing Cross Hospital), James Jackson(Adelphi Group (United Kingdom)), Edward Leen(Imperial College Healthcare NHS Trust)
Endocrine Abstracts
March 16, 2017
10.1530/endoabs.48.o8
Cited by 0

Related Papers

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
|JAMA|2018|406
A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer
|Surgery|2011|266
Association between high serum total cortisol concentrations and mortality from COVID-19
|The Lancet Diabetes & Endocrinology|2020|260
Thyroid Function Before, During, and After COVID-19
|The Journal of Clinical Endocrinology & Metabolism|2020|220
Randomized clinical trial of Ligasure™<i>versus</i> open haemorrhoidectomy
|British journal of surgery|2002|154